Health indices closed out the week fairly flat as some stocks benefitted from analyst actions, while others fell because of trial results and lawsuits.Cadence Pharmaceuticals (CADX) said Friday that in a pivotal late-stage trial its IV-administered Acetavance for pain and fever didn't meet a primary endpoint.
Friday's Health Winners & Losers
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.